Fox David Morton reported derivative exercise involving 6,534 derivative units of MediWound Ltd. on Nov 10, 2026

Derivative exercise
Form 4 code X. Exercise of an in-the-money or at-the-money derivative security, except a transaction reported with code M.
Director
DIR
Filed Nov 12, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
—Shares × reported price
Shares traded
6,534Series A Warrants
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
Nov 10, 2026Derivative exercise
Filed
Nov 12, 2026, 7:31 AM ET2-day reporting delay
Accession
0001178913-26-005157Code X · Transaction 398205
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 10, 2026Derivative exercise6,534$13.48$88,045.65Trade 398204
2 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

MDWD price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MDWD · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −9.6%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date. F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. F3: The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date. F4: On November 10, 2026, the Reporting Person exercised Series A Warrants to purchase 6,534 ordinary shares at an exercise price of $13.475 per share, paying the aggregate exercise price in cash. The Reporting Person did not sell any of the ordinary shares acquired upon the exercise. No separate price was paid for the Series A Warrants upon exercise. The exercise price is reported in column 2 and in Table I.